IDPH--Positive preliminary results for pivotal trial of ID Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IDPH--Positive preliminary results for pivotal trial of ID

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Roger Cranwill who wrote (945)	6/4/1997 6:02:00 PM
From: Brad C. Dunlap	of 1762

Hi Roger, I am aware of the latest info that was made public on C2B8 concerning duraton of responses, and this was probably discussed at the annual meeting, however, there is much interest from all three analysts on the new data that will be released this month. This updated info I a sure you has not previously been made public. Also, never has there been any info made public on retreats and whether the response durations fall into a similar pattern as chemo is a big unknown. I do know as of approx 6 months ago there were a few patients that were retreated but once again nothing has been made public. I would love to believe that C2B8 response durations do not fall into the same mold as chemo but at this stage in the game, I'll believe it when I see how C2B8 passes the test of time and over large number of patients. Actually my non-scientific mind can extrapulate from the detailed data from previous patients a speculative thought as to why C2B8 might be even more efficacious on retreats from a simple observation. The patients that responded best to C2B8 were patients that obsorbed more on the first infusion. There was a strong positive correlation between the patients responses and the absorbtion of C2B8. What I found interesting is that after each transfusion increasing amounts of C2B8 was obsorbed by the patients. Since increased obsorbtions increased the efficacy. It would appear to me that the patients that are retreated would follow the pattern of obsorbing more of the drug which correlates to stronger efficacy. Now, Idec confirms the facts but in NO WAY would comment on my crazy assumption until there is clinical data on retreats. Anyway, Idec sure had a nice day in the mkt.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next